Biography and Research Information
OverviewAI-generated summary
Hannah E. Shaw's research investigates the pharmacological effects and abuse liability of novel psychoactive substances, particularly arylcyclohexylamines and synthetic opioids, in rodent models. Her work examines the neurocognitive and behavioral impacts of these compounds, including their potential for producing psychosis-like effects and their role in exacerbating respiratory depression. Shaw also studies the effects of psychostimulants on locomotor activity in mice with a genetic background relevant to autism spectrum disorder and attention deficit hyperactivity disorder. She has published five papers, with her most recent work appearing in 2025. Shaw collaborates with researchers at the University of Arkansas for Medical Sciences, including William E. Fantegrossi, Brenda M. Gannon, Jeffery H. Moran, and Marina Avram.
Metrics
- h-index: 3
- Publications: 6
- Citations: 19
Selected Publications
-
Effects of Psychedelics Lysergic Acid Diethylamide and <i>R</i> (–)-2,5-Dimethoxy-4-Iodoamphetamine on Oral Opioid Consumption and Naloxone-Precipitated Withdrawal in Male C57Bl/6J Mice (2026)
-
Effects of psychostimulants on locomotor activity in the BTBR T+ Itpr3tf/J mouse: implications for comorbid autism spectrum disorder and attention deficit hyperactivity disorder (2025)
-
Effects of orally self-administered furanyl fentanyl and acryl fentanyl in mice: antinociception, dependence and withdrawal, and defense of consumption (2025)
-
Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice (2025)
-
Phencyclidine-Like Abuse Liability and Psychosis-Like Neurocognitive Effects of Novel Arylcyclohexylamine Drugs of Abuse in Rodents (2024)
Collaboration Network
Top Collaborators
William E. Fantegrossi
University of Arkansas for Medical Sciences
5 shared publications
In database
- Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder
- Phencyclidine-Like Abuse Liability and Psychosis-Like Neurocognitive Effects of Novel Arylcyclohexylamine Drugs of Abuse in Rodents
- Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice
- Effects of orally self-administered furanyl fentanyl and acryl fentanyl in mice: antinociception, dependence and withdrawal, and defense of consumption
- Effects of psychostimulants on locomotor activity in the BTBR T+ Itpr3tf/J mouse: implications for comorbid autism spectrum disorder and attention deficit hyperactivity disorder
Harpreet Kaur
Oncolytics Biotech (Canada) (CA)
2 shared publications
- Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder
- Effects of psychostimulants on locomotor activity in the BTBR T+ Itpr3tf/J mouse: implications for comorbid autism spectrum disorder and attention deficit hyperactivity disorder
Stephen A. Fagot
University of Arkansas for Medical Sciences
2 shared publications
In database
- Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder
- Effects of psychostimulants on locomotor activity in the BTBR T+ Itpr3tf/J mouse: implications for comorbid autism spectrum disorder and attention deficit hyperactivity disorder
Brenda M. Gannon
University of Arkansas for Medical Sciences
2 shared publications
In database
- Phencyclidine-Like Abuse Liability and Psychosis-Like Neurocognitive Effects of Novel Arylcyclohexylamine Drugs of Abuse in Rodents
- Effects of orally self-administered furanyl fentanyl and acryl fentanyl in mice: antinociception, dependence and withdrawal, and defense of consumption
Marina Avram
Arkansas Department of Agriculture
2 shared publications
In database
- Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice
- Effects of orally self-administered furanyl fentanyl and acryl fentanyl in mice: antinociception, dependence and withdrawal, and defense of consumption
Jeffery H. Moran
University of Arkansas for Medical Sciences
2 shared publications
In database
- Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice
- Effects of orally self-administered furanyl fentanyl and acryl fentanyl in mice: antinociception, dependence and withdrawal, and defense of consumption
Sedat Karabulut
University of Windsor (CA)
1 shared publication
- Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder
James W. Gauld
University of Windsor (CA)
1 shared publication
- Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder
Kalee N. Holloway
1 shared publication
In database
- Balancing Therapeutic Efficacy and Safety of MDMA and Novel MDXX Analogues as Novel Treatments for Autism Spectrum Disorder
Dylan R. Patel
University of Arkansas for Medical Sciences
1 shared publication
In database
- Phencyclidine-Like Abuse Liability and Psychosis-Like Neurocognitive Effects of Novel Arylcyclohexylamine Drugs of Abuse in Rodents
Lauren R. Fitzgerald
University of Arkansas for Medical Sciences
1 shared publication
In database
- Phencyclidine-Like Abuse Liability and Psychosis-Like Neurocognitive Effects of Novel Arylcyclohexylamine Drugs of Abuse in Rodents
Theresa M. Carbonaro
United States Department of Justice (US)
1 shared publication
- Phencyclidine-Like Abuse Liability and Psychosis-Like Neurocognitive Effects of Novel Arylcyclohexylamine Drugs of Abuse in Rodents
Chad R. Johnson
University of Maryland, Baltimore (US)
1 shared publication
- Phencyclidine-Like Abuse Liability and Psychosis-Like Neurocognitive Effects of Novel Arylcyclohexylamine Drugs of Abuse in Rodents
J S James
University of Arkansas for Medical Sciences
1 shared publication
In database
- Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice
Jessica Thrush
University of Arkansas for Medical Sciences
1 shared publication
In database
- Synthetic cannabinoid receptor agonists exacerbate fentanyl-elicited respiratory depression and confer resistance to naloxone rescue in mice
Similar Researchers
Based on overlapping research topics
Stephen A. Fagot
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Neuroscience and Neuropharmacology Research
Substance Abuse Treatment and Outcomes
Lauren R. Fitzgerald
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Neuroscience and Neuropharmacology Research
Substance Abuse Treatment and Outcomes
Justin R. Nickell
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Neuroscience and Neuropharmacology Research
Substance Abuse Treatment and Outcomes
Dylan R. Patel
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Neuroscience and Neuropharmacology Research
Substance Abuse Treatment and Outcomes
Scott M. Apana
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Neuroscience and Neuropharmacology Research
Substance Abuse Treatment and Outcomes
Kyle Urquhart
University of Arkansas for Medical Sciences
Pharmacological Effects and Toxicity Studies
Neuroscience and Neuropharmacology Research
Substance Abuse Treatment and Outcomes